Literature DB >> 23246508

A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.

Jessica Liu1, Mei-Hsuan Lee, Richard Batrla-Utermann, Chin-Lan Jen, Uchenna H Iloeje, Sheng-Nan Lu, Li-Yu Wang, San-Lin You, Chuhsing K Hsiao, Hwai-I Yang, Chien-Jen Chen.   

Abstract

BACKGROUND & AIMS: Seroclearance of hepatitis B surface antigen (HBsAg) is the most ideal end point in the treatment of chronic hepatitis B. This study develops a predictive scoring system to assess whether the addition of serum levels HBsAg may improve the predictability of HBsAg loss.
METHODS: This study included 2491 untreated participants with genotype B or C HBV infection, who were HBsAg-seropositive, HBeAg-seronegative, anti-HCV-seronegative, and cirrhosis free at study entry. Regression coefficients of predictors in Cox Regression models were converted into integer scores for predicting HBsAg seroclearance. Predictive accuracy was assessed with area under the receiver operating characteristic curves (AUROC), and predictive accuracies of models with and without serum HBsAg levels were compared.
RESULTS: Low serum levels of both HBsAg and HBV DNA were the strongest predictors of spontaneous HBsAg seroclearance. Compared to baseline serum HBsAg levels ≥1000 IU/ml, the multivariate adjusted rate ratio of spontaneous HBsAg seroclearance was 10.96 (7.92-15.16) for those with baseline serum HBsAg levels <100 IU/ml. The predictive ability of HBsAg levels was modified by HBV viral load, showing a weaker effect in those with higher viral loads, and the strongest effect among those with undetectable viral loads. The inclusion of serum HBsAg levels greatly improved the AUROC for predicting HBsAg seroclearance at the fifth (from 0.79 [0.787-0.792] to 0.89 [0.889-0.891]) and tenth year (from 0.73 [0.728-0.732] to 0.84 [0.839-0.841]) after study entry.
CONCLUSIONS: Incorporated into an easy-to-use scoring system, HBV viral load and quantitative serum HBsAg levels can accurately predict HBsAg seroclearance.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23246508     DOI: 10.1016/j.jhep.2012.12.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

1.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Authors:  Yanbing Zeng; Mingliang Luo; Jianlin Lin; Hanqing He; Xuan Deng; Shuyun Xie; Ya Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

Review 2.  Hepatitis B virus genotypes and variants.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

3.  Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.

Authors:  Kali Zhou; Caitlin Contag; Evans Whitaker; Norah Terrault
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-01-22

Review 4.  When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response.

Authors:  Wonseok Kang; Jun Yong Park
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 5.  Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia.

Authors:  Hwai-I Yang; Mei-Hsuan Lee; Jessica Liu; Chien-Jen Chen
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 6.  Molecular mechanisms underlying HBsAg negativity in occult HBV infection.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-24       Impact factor: 3.267

7.  Chronic hepatitis B: the demise of the 'inactive carrier' phase.

Authors:  Apostolos Koffas; Manoj Kumar; Upkar S Gill; Ankur Jindal; Patrick T F Kennedy; S K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

8.  HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes.

Authors:  Tien Huey Lim; Edward Gane; Chris Moyes; Barry Borman; Chris Cunningham
Journal:  Hepatol Int       Date:  2016-03-08       Impact factor: 6.047

9.  Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection.

Authors:  L H Nguyen; J Hoang; N H Nguyen; V D Vu; C Wang; H N Trinh; J Li; J Q Zhang; M H Nguyen
Journal:  Aliment Pharmacol Ther       Date:  2016-07-01       Impact factor: 8.171

Review 10.  Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection.

Authors:  Yun-Fan Liaw
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-09-02       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.